These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 18250364)

  • 1. A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity.
    Dietz JD; Du S; Bolten CW; Payne MA; Xia C; Blinn JR; Funder JW; Hu X
    Hypertension; 2008 Mar; 51(3):742-8. PubMed ID: 18250364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The L-, N-, and T-type triple calcium channel blocker benidipine acts as an antagonist of mineralocorticoid receptor, a member of nuclear receptor family.
    Kosaka H; Hirayama K; Yoda N; Sasaki K; Kitayama T; Kusaka H; Matsubara M
    Eur J Pharmacol; 2010 Jun; 635(1-3):49-55. PubMed ID: 20307534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereochemical requirements for the mineralocorticoid receptor antagonist activity of dihydropyridines.
    Arhancet GB; Woodard SS; Dietz JD; Garland DJ; Wagner GM; Iyanar K; Collins JT; Blinn JR; Numann RE; Hu X; Huang HC
    J Med Chem; 2010 May; 53(10):4300-4. PubMed ID: 20408553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist.
    Arai K; Homma T; Morikawa Y; Ubukata N; Tsuruoka H; Aoki K; Ishikawa H; Mizuno M; Sada T
    Eur J Pharmacol; 2015 Aug; 761():226-34. PubMed ID: 26073023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blockade of T-type voltage-dependent Ca2+ channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R.
    Akizuki O; Inayoshi A; Kitayama T; Yao K; Shirakura S; Sasaki K; Kusaka H; Matsubara M
    Eur J Pharmacol; 2008 Apr; 584(2-3):424-34. PubMed ID: 18331727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological treatment of aldosterone excess.
    Deinum J; Riksen NP; Lenders JW
    Pharmacol Ther; 2015 Oct; 154():120-33. PubMed ID: 26213109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Competitive and cooperative effects of Bay K8644 on the L-type calcium channel current inhibition by calcium channel antagonists.
    Zahradníková A; Minarovic I; Zahradník I
    J Pharmacol Exp Ther; 2007 Aug; 322(2):638-45. PubMed ID: 17475903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular pharmacology of the calcium channel: evidence for subtypes, multiple drug-receptor sites, channel subunits, and the development of a radioiodinated 1,4-dihydropyridine calcium channel label, [125I]iodipine.
    Glossmann H; Ferry DR; Goll A; Rombusch M
    J Cardiovasc Pharmacol; 1984; 6 Suppl 4():S608-21. PubMed ID: 6083403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mineralocorticoid receptor blockade and calcium channel blockade have different renoprotective effects on glomerular and interstitial injury in rats.
    Du J; Fan YY; Hitomi H; Kiyomoto H; Kimura S; Kong CZ; Noma T; Kohno M; Nishiyama A; Nakano D
    Am J Physiol Renal Physiol; 2009 Sep; 297(3):F802-8. PubMed ID: 19535572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitory effects of a dihydropyridine calcium channel blocker on renal injury in aldosterone-infused rats.
    Fan YY; Kohno M; Nakano D; Hitomi H; Nagai Y; Fujisawa Y; Lu XM; Fu H; Du J; Ohmori K; Hosomi N; Kimura S; Kiyomoto H; Nishiyama A
    J Hypertens; 2009 Sep; 27(9):1855-62. PubMed ID: 19633569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of voltage-gated calcium channels in potassium-stimulated aldosterone secretion from rat adrenal zona glomerulosa cells.
    Uebele VN; Nuss CE; Renger JJ; Connolly TM
    J Steroid Biochem Mol Biol; 2004 Oct; 92(3):209-18. PubMed ID: 15555914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dihydropyridine calcium channel antagonists disrupt migrating myoelectric complexes and counteract intestinal disorders associated with morphine withdrawal diarrhea.
    Thollander M; Hellström PM; Svensson TH
    Scand J Gastroenterol; 1993 Feb; 28(2):137-44. PubMed ID: 8441907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1.
    Amazit L; Le Billan F; Kolkhof P; Lamribet K; Viengchareun S; Fay MR; Khan JA; Hillisch A; Lombès M; Rafestin-Oblin ME; Fagart J
    J Biol Chem; 2015 Sep; 290(36):21876-89. PubMed ID: 26203193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calcium channel antagonists and human immunodeficiency virus coat protein-mediated neuronal injury.
    Lipton SA
    Ann Neurol; 1991 Jul; 30(1):110-4. PubMed ID: 1656845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Five different profiles of dihydropyridines in blocking T-type Ca(2+) channel subtypes (Ca(v)3.1 (alpha(1G)), Ca(v)3.2 (alpha(1H)), and Ca(v)3.3 (alpha(1I))) expressed in Xenopus oocytes.
    Furukawa T; Nukada T; Namiki Y; Miyashita Y; Hatsuno K; Ueno Y; Yamakawa T; Isshiki T
    Eur J Pharmacol; 2009 Jun; 613(1-3):100-7. PubMed ID: 19401195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Symptoms and the distress they cause: comparison of an aldosterone antagonist and a calcium channel blocking agent in patients with systolic hypertension.
    Hollenberg NK; Williams GH; Anderson R; Akhras KS; Bittman RM; Krause SL
    Arch Intern Med; 2003 Jul; 163(13):1543-8. PubMed ID: 12860576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel 1,4-Dihydropyridine Derivatives as Mineralocorticoid Receptor Antagonists.
    Pérez-Gordillo FL; Serrano-Morillas N; Acosta-García LM; Aranda MT; Passeri D; Pellicciari R; Pérez de Vega MJ; González-Muñiz R; Alvarez de la Rosa D; Martín-Martínez M
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcium channel agonists and antagonists: effects of chronic treatment on pituitary prolactin synthesis and intracellular calcium.
    Hinkle PM; Jackson AE; Thompson TM; Zavacki AM; Coppola DA; Bancroft C
    Mol Endocrinol; 1988 Nov; 2(11):1132-8. PubMed ID: 3221879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel dihydropyridine with 3-aryl meta-hydroxyl substitution blocks L-type calcium channels in rat cardiomyocytes.
    Galvis-Pareja D; Zapata-Torres G; Hidalgo J; Ayala P; Pedrozo Z; Ibarra C; Diaz-Araya G; Hall AR; Vicencio JM; Nuñez-Vergara L; Lavandero S
    Toxicol Appl Pharmacol; 2014 Aug; 279(1):53-62. PubMed ID: 24844443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological in vitro studies of the new 1,4-dihydropyridine calcium antagonist lercanidipine.
    Guarneri L; Angelico P; Ibba M; Poggesi E; Taddei C; Leonardi A; Testa R
    Arzneimittelforschung; 1996 Jan; 46(1):15-24. PubMed ID: 8821512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.